Vadim V. Kozlov

Timakova Street, 2/12
Novosibirsk, NVS 630117, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

A Multi-Level miRNA Regulatory Network Associated with IRF1 Expression in Non-Small Cell Lung Cancer: In Silico Identification of Candidate Biomarkers for Immunotherapy Response.

A Multi-Level miRNA Regulatory Network Associated with IRF1 Expression in Non-Small Cell Lung Cancer: In Silico Identification of Candidate Biomarkers for Immunotherapy Response.

Journal: International journal of molecular sciences

Published: April 13, 2026

Real-world testing practices, treatment patterns, and outcomes of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor-mutated advanced/metastatic non-small cell lung cancer: An international study.

Real-world testing practices, treatment patterns, and outcomes of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor-mutated advanced/metastatic non-small cell lung cancer: An international study.

Journal: Cancer treatment and research communications

Published: February 05, 2026

Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].

Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 31, 2025

Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.

Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 15, 2025

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.

Journal: The New England journal of medicine

Published: June 02, 2025

Development of Ex Vivo Analysis for Examining Cell Composition, Immunological Landscape, Tumor and Immune Related Markers in Non-Small-Cell Lung Cancer.

Development of Ex Vivo Analysis for Examining Cell Composition, Immunological Landscape, Tumor and Immune Related Markers in Non-Small-Cell Lung Cancer.

Journal: Cancers

Published: June 05, 2024

Smoking-Mediated miR-301a/IRF1 Axis Controlling Immunotherapy Response in Lung Squamous Cell Carcinoma Revealed by Bioinformatic Analysis.

Smoking-Mediated miR-301a/IRF1 Axis Controlling Immunotherapy Response in Lung Squamous Cell Carcinoma Revealed by Bioinformatic Analysis.

Journal: Cancers

Published: May 12, 2024

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 16, 2024

Tumor suppressor PTEN regulation by tobacco smoke in lung squamous-cell carcinoma based on bioinformatics analysis.

Tumor suppressor PTEN regulation by tobacco smoke in lung squamous-cell carcinoma based on bioinformatics analysis.

Journal: Heliyon

Published: May 24, 2023

New Insight into the Role of AhR in Lung Carcinogenesis.

New Insight into the Role of AhR in Lung Carcinogenesis.

Journal: Biochemistry. Biokhimiia

Published: December 12, 2022

Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.

Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.

Journal: European urology oncology

Published: July 21, 2022

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 23, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026